Views & Analysis The EMA’s Adaptive Pathways: are safety concerns exaggerated... Companies still need to provide a compelling case for efficacy
News Samsung Bioepis' Remicade rival approved in EU Merck, Sharp and Dohme's (MSD) inflammatory diseases blockbuster Remicade (infliximab) faces further biosimilar competition after Samsung Bioepis' rival, Flixabi, was approved in Europe.
News J&J's oral IL-23 drug backed for psoriasis in EU J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
